Efficacy of bortezomib combined with Hyper‑CVAD in adults with relapsed acute lymphoblastic leukemia or positive measurable residual disease; effect of bortezomib in leukemia
10.1007/s44313-024-00050-6
- Author:
Christian Omar Ramos PEÑAFIEL
1
;
Daniela Pérez SÁMANO
;
Adán Germán Gallardo RODRÍGUEZ
;
Camila Terreros PALACIO
;
Irma Olarte CARRILLO
;
Carlos Martínez MURILLO
;
Gilberto Barranco LAMPÓN
;
Álvaro Cabrera GARCÍA
;
Adolfo Martínez TOVAR
Author Information
1. Hematology Department, General Hospital of Mexico “Dr. Eduardo Liceaga, Mexico City, Mexico
- Publication Type:RESEARCH
- From:Blood Research
2025;60():4-
- CountryRepublic of Korea
- Language:English
-
Abstract:
Purpose:Despite advances in the treatment of adult acute lymphoblastic leukemia (ALL), relapse remains the most significant challenge in improving prognosis. Measurable residual disease (MRD) assessment can predict bone marrow relapse based on MRD positivity. As access to innovative therapies remains limited because of the high cost, chemotherapy is the widely utilized treatment option. The efficacy of a combination of bortezomib and Hyper-CVAD has been reported in patients with multiple myeloma; however, its efficacy has not yet been confirmed in patients with ALL.
Methods:This prospective cohort study involved patients with ALL who presented with MRD-positive results or relapse and received treatment with a combination of bortezomib and Hyper-CVAD at two reference centers in Mexico City.
Results:Of the 20 patients with positive MRD included in this study, 60% (n = 12) exhibited MRD negative results after combination treatment, 30% (n = 6) persisted positive MRD results, and 10% (n = 2) passed away. Of the 23 patients with bone marrow relapse, 43.5% (n = 10) achieved a second complete remission (2CR), 34.8% (n = 6) exhibited refractory status, and 21.7% (n = 5) passed away. To achieve a 2CR, 20% (n = 2) patients required less than four cycles of treatment, 50% (n = 5) required four cycles (two A and B cycles each), and 30% (n = 3) required six cycles.
Conclusion:The combination of bortezomib and Hyper-CVAD treatment exhibited better results in achieving MRD negative results, indicating its potential as a promising first-line treatment strategy for ALL.
